Zobrazeno 1 - 10 of 162 pro vyhledávání: '"Campelo MD"'
1
Akademický článek
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
Autor: Giannis Mountzios, MD, PhD, David Planchard, MD, PhD, Giulio Metro, MD, PhD, Dora Tsiouda, Arsela Prelaj, MD, Sofia Lampaki, MD, PhD, Walid Shalata, MD, Mariona Riudavets, Petros Christopoulos, MD, PhD, Nicolas Girard, MD, PhD, Víctor Albarrán-Artahona, Rosario Garcia Campelo, MD, PhD, Konstantinos Samitas, MD, PhD, Giuseppe Luigi Banna, MD, Ioannis Boukovinas, MD, PhD, Abed Agbarya, MD, PhD, Anna Koumarianou, MD, Eleni-Isidora Perdikouri, Paris Kosmidis, Helena Linardou, MD, PhD, David Mauri, MD, PhD, Dimitrios Mavroudis, MD, PhD, Ilias Athanasiadis, MD, PhD, Haralambos Kalofonos, Nikolaos Xenidis, MD, PhD, Ippokratis Korantzis, MD, Alexandros Ardavanis, Grigorios Rallis, MD, Achille Bottiglieri, Konstantinos Efthymiadis, MD, Georgios Oikonomopoulos, MD, Alexandros Kokkalis, MD, Emmanouil Saloustros, MD, PhD, Nikolaos Tsoukalas, MD, Dimitra Bartzi, MD, Panagiota Economopoulou, Amanda Psyrri, MD, PhD, Martin Reck, Giuseppe Lo Russo, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100433- (2023)
Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European registry for patients w
Externí odkaz: https://doaj.org/article/1da16fe8f3c8428eb04732eb21d2f835
Zobrazit plný text záznamu
2
Akademický článek
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
Autor: Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz: https://doaj.org/article/08a2152e29af4e089606394482732718
Zobrazit plný text záznamu
3
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Autor: Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu., Watts J; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Radinoff A; University Hospital Sveti Ivan Rislki, Sofia, Bulgaria., Sangerman MA; Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain., Cerrano M; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy., Lopez PF; Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Campelo MD; University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain., Graux C; Department of Hematology, Université Catholique de Louvain, CHU UCL Namur (Godinne site), Yvoir, Belgium., Liesveld J; The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA., Selleslag D; AZ Sint Jan Brugge-Oostende, Brugge, Belgium., Tzvetkov N; MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria., Fram RJ; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Zhao D; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Bell J; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Friedlander S; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Faller DV; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Adès L; AP-HP, Hôpital Saint Louis, Paris, France.; University of Paris and INSERM U944, Paris, France.
Publikováno v: Leukemia [Leukemia] 2021 Dec; Vol. 35 (12), pp. 3637.
Zobrazit plný text záznamu
4
Akademický článek
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Autor: Janusz K; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Izquierdo MM; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Cadenas FL; Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain., Ramos F; Hematología, Hospital Universitario de León, León, Spain., Sánchez JMH; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Lumbreras E; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Robledo C; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Del Real JS; Hematología, Hospital Universitario de León, León, Spain., Caballero JC; Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain., Collado R; Hematología, Hospital General Universitario de Valencia, Valencia, Spain., Bernal T; Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain., Pedro C; Hematología, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain., Insunza A; Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain., de Paz R; Hematología, Hospital Universitario de la Paz, Madrid, Spain., Xicoy B; Hematología, Hospital Universitari Germans Trias I Pujol, Instituto Catalán de Oncología (ICO), Badalona, Spain., Salido E; Hospital Universitario de Canarias, Universidad La Laguna, San Cristóbal de La Laguna, Spain., García JS; Hematología, Hospital Universitario Reina Sofía, Córdoba, Spain., Mínguez SS; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., García CM; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Muñoz AMS; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Barba MS; Departamento de Estadística, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain., Rivas JMH; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain., Abáigar M; Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-Universidad de Salamanca (IBMCC, USAL-CSIC); Genética Molecular en Oncohematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Campelo MD; Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain. mdiezcampelo@usal.es.
Publikováno v: Annals of hematology [Ann Hematol] 2021 Aug; Vol. 100 (8), pp. 1995-2004. Date of Electronic Publication: 2021 Jan 06.
Zobrazit plný text záznamu
6
Report
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Autor: Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu., Watts J; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Radinoff A; University Hospital Sveti Ivan Rislki, Sofia, Bulgaria., Sangerman MA; Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain., Cerrano M; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy., Lopez PF; Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain., Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Campelo MD; University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain., Graux C; Department of Hematology, Université Catholique de Louvain, CHU UCL Namur (Godinne site), Yvoir, Belgium., Liesveld J; The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA., Selleslag D; AZ Sint Jan Brugge-Oostende, Brugge, Belgium., Tzvetkov N; MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria., Fram RJ; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Zhao D; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Bell J; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Friedlander S; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Faller DV; Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Adès L; AP-HP, Hôpital Saint Louis, Paris, France.; University of Paris, and INSERM U944, Paris, France.
Publikováno v: Leukemia [Leukemia] 2021 Jul; Vol. 35 (7), pp. 2119-2124. Date of Electronic Publication: 2021 Jan 22.
Zobrazit plný text záznamu
7
Editorial & Opinion
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Autor: Park S; Centre hospitalo-universitaire (CHU) Grenoble Alpes, Service d'hématologie, Université Grenoble Alpes, INSERM U1209, Institute for Advanced Biosciences, UMR CNRS 5309, CS 10217, 38043, GRENOBLE Cedex 09, France. Electronic address: spark@chu-grenoble.fr., Hamel JF; CHU d'Angers, Angers, France., Toma A; Hôpitaux Universitaires Henri Mondor, Hematologie-DMU Gériatrie, Assistance Publique Hopitaux de Paris (AP-HP), Paris, France., Kelaidi C; Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece., Thépot S; CHU Angers, Université d'Angers, Inserm, Unité 1232, LabEx IGO, Angers, France., Campelo MD; Hospital Universitario de Salamanca, Salamanca, GESMD, Spain., Santini V; Hematology Unit-AOU Careggi, University of Florence, Firenze, Italy., Sekeres MA; Division of Hematology, Sylvester Comprehensive cancer Center, University of Miami, Miami, Florida, USA., Komrokji R; H. Lee Moffitt Cancer Center, Tampa, Florida, USA., Steensma D; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Balleari E; Medicina Interna, Ospedale Imperia ASL1, Imperiese via s. Agata, 57 docente Dottorato Ematologia Oncologia e Medicina Interna Clinico-Traslazionale Università di Genova, Italy., Götze KS; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, München, Germany., Kotsianidis I; Democritus University of Thrace, University Hospital of Alexandroupolis, Department of Hematology, Alexandroupolis, Greece., Guerci-Bresler A; CHU de Nancy, France., Stamatoullas A; Centre Henri Becquerel (CHB), Rouen, France., Sanz GF; Hospital Universitario de Salamanca, Salamanca, GESMD, Spain., Germing U; Heinrich-Heine University Dusseldorf, Universitätsklinikum, Dept. of Hematology, Oncology and Clinical Immunology, Dusseldorf, Germany., Fenaux P; Hôpital Saint Louis, APHP, and Université de Paris, France.
Publikováno v: Leukemia research [Leuk Res] 2020 Dec; Vol. 99, pp. 106472. Date of Electronic Publication: 2020 Nov 05.
Zobrazit plný text záznamu
8
Akademický článek
A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
Autor: Cadenas FL; Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain., Bua BR; Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain., Campelo MD; Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain., Rieu JB; Central Haematology Laboratory, Cancer University Institute of Toulouse Oncopole, Toulouse, France., Bain BJ; Centre for Haematology, St Mary's Hospital campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.
Publikováno v: American journal of hematology [Am J Hematol] 2020 Oct; Vol. 95 (10), pp. 1214-1215. Date of Electronic Publication: 2020 May 05.
Zobrazit plný text záznamu
9
Report
Rejection of hemolyzed samples can jeopardize patient safety.
Autor: Barbato L; Pharmacy, University Hospital of Verona, Italy., Campelo MD; Clinical Laboratory Bioanalise, Teresina, Piaui, Brazil.; Faculdade Integral Diferencial Facid-Wyden, Teresina, Piaui, Brazil., Pigozzo S; Pharmacy, University Hospital of Verona, Italy.; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy., Realdon N; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy., Gandini A; Pharmacy, University Hospital of Verona, Italy., Barbazza R; Pharmacy, University Hospital of Verona, Italy., Coêlho ML; Faculdade Integral Diferencial Facid-Wyden, Teresina, Piaui, Brazil., Bovo C; Health Management, University Hospital of Verona, Italy., Marini P; Pharmacy, University Hospital of Verona, Italy., Lima-Oliveira G; Faculdade Integral Diferencial Facid-Wyden, Teresina, Piaui, Brazil.; Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy.; Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI), Montevideo, Uruguay.
Publikováno v: EJIFCC [EJIFCC] 2020 Mar 20; Vol. 31 (1), pp. 15-20. Date of Electronic Publication: 2020 Mar 20 (Print Publication: 2020).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje